# A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors

> **NCT07730190** · PHASE1 · RECRUITING · sponsor: **Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.** · enrollment: 145 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** TQB6426 for Injection

## Key facts

- **NCT ID:** NCT07730190
- **Lead sponsor:** Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-25
- **Primary completion:** 2027-08
- **Final completion:** 2028-05
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2026-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07730190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07730190, "A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07730190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*